Celltrion said on the 18th that prescriptions for Zymfentra in the United States in January this year rose 213% from a year earlier. Zymfentra is a product that converts the autoimmune disease treatment Remsima into a subcutaneous injection formulation. After its U.S. debut in 2024, it set an all-time high for prescriptions this time.
The volume of Zymfentra shipped to U.S. wholesale and retail distributors in February increased 3.5 times from a year earlier. Because biopharmaceuticals have a shelf life, medical institutions place orders while watching prescription trends for patients, the company said.
Celltrion is pursuing a 3P (provider·payer·patient) strategy in the United States targeting medical staff, insurers, and patients. Chair Seo Jung-Jin of Celltrion and employees met medical staff to promote Zymfentra, and signed formulary listing contracts with insurers including the three largest U.S. pharmacy benefit managers (PBMs). It also conducted marketing targeting patients.
A Celltrion official said, "The 3P strategy is leading to more prescriptions," and added, "We will pursue active sales so growth can continue."